We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+2.7%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
-$430M
Cap. Flow
-$140M
Cap. Flow %
-9.32%
Top 10 Hldgs %
47.39%
Holding
116
New
31
Increased
19
Reduced
31
Closed
29
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$31.2M
2
OGN icon
Organon & Co
OGN
+$23M
3
CYH icon
Community Health Systems
CYH
+$19.2M
4
RCM icon
R1 RCM Inc. Common Stock
RCM
+$18.6M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$17.3M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$71.3M
2
GSK icon
GSK
GSK
+$28.4M
3
TGTX icon
TG Therapeutics
TGTX
+$27.2M
4
ELV icon
Elevance Health
ELV
+$20.5M
5
CTLT icon
CATALENT, INC.
CTLT
+$17.2M

Sector Composition

Rank Sector Weight
1 Healthcare 65.27%
2 Miscellaneous 33.54%
3 Industrials 1.14%
4 Financials 0.05%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MNKD icon
101
MannKind Corp
MNKD
$977M
– –
-2,165,383
Closed -$8.49M –
NVAX icon
102
Novavax
NVAX
$1.84B
– –
-33,473
Closed -$6.13M –
PRTA icon
103
Prothena Corp
PRTA
$428M
– –
-68,575
Closed -$1.72M –
QDEL icon
104
QuidelOrtho
QDEL
$917M
– –
-4,132
Closed -$529K –
SRDX icon
105
DELISTED
Surmodics
SRDX
– –
-47,906
Closed -$2.69M –
XGN icon
106
Exagen
XGN
$186M
– –
-104,437
Closed -$1.83M –
CTLT icon
107
DELISTED
CATALENT, INC.
CTLT
– –
-163,114
Closed -$17.2M –
DCPH icon
108
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-345,717
Closed -$15.5M –
RAD
109
DELISTED
Rite Aid Corporation
RAD
– –
-54,025
Closed -$1.11M –
APTO
110
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-178
Closed -$478K –
OTIC
111
CALL
DELISTED
Otonomy, Inc.
OTIC
– –
-198,400
Closed -$506M –
CFMS
112
DELISTED
Conformis, Inc. Common Stock
CFMS
– –
-61,679
Closed -$1.53M –
ALXN
113
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-465,983
Closed -$71.3M –
LMNX
114
DELISTED
Luminex Corp
LMNX
– –
-135,471
Closed -$4.33M –
FPRX
115
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-93,280
Closed -$3.51M –
BHVN icon
116
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-242,172
Closed -$16.6M –
1 2 3 4
5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Eversept Partners held 116 positions worth $1.5B, down 22% from $1.93B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners withdrew a net $140M in Q2 2021, closing 29 positions and reducing 31 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $71.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Eversept Partners opened a new position in Bristol-Myers Squibb worth $32M.

  • Eversept Partners's largest Q2 2021 buy was Bristol-Myers Squibb: 478,328 shares worth $32M.
  • Eversept Partners added most to Community Health Systems in Q2 2021, an estimated $19.2M increase.
  • Eversept Partners's biggest Q2 2021 reduction was GSK, cutting an estimated $28.4M.
  • Eversept Partners fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $71.3M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.5B portfolio in Q2 2021.
  • Eversept Partners opened 31 new positions and closed 29 in Q2 2021.
  • Eversept Partners's portfolio value fell 22% quarter-over-quarter to $1.5B.

Based on Eversept Partners's 13F filing for Q2 2021, filed 16 Aug 2021.